Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction - DOSE Finding Study

NCT04270760 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

281

Enrollment

INDUSTRY

Sponsor class

Conditions

Cardiovascular Disease

Interventions

DRUG: Olpasiran
DRUG: Placebo

Sponsor

Amgen